Recent News

• 03.26.2026 - Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
• 03.16.2026 - Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
• 11.19.2025 - Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Recent Filings

• 03.20.2026 - 8-K Current report
• 03.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 03.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.06.2026 - 8-K Current report
• 02.26.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 02.26.2026 - DEF 14A Other definitive proxy statements
• 02.09.2026 - PRE 14A Other preliminary proxy statements
• 12.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.09.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]